I know its always been raised as a possibility but noticed it...

I know its always been raised as a possibility but noticed it has also been covered  in the latest 1103/somavert patent.
http://patentscope.wipo.int/search/...e tachas PCT/AU2013/000095&tab=PCTDescription

From bottom of extract.....
"Example 7: Co-administration of an antisense oligonucleotide and Somavert for the treatment of cancer
Groups of 15 patients with cancer associated with increased IGF-I are to be dosed with 200 mg ATL1103 once or twice weekly dosing for 13 weeks and either (i) 30 mg once weekly Somavert or (ii) 30 mg twice weekly Somavert for 13 weeks or (iii) 80 mg once weekly or (iv) 80 mg twice weekly Somavert.
Control groups: ATL1103 or Somavert is to be administered alone, with patients standard medication, for a similar 13 week period to cancer patients.
Treatment is to be continued with the same or increased or lower doses of Somavert, and with the same or increased or lower doses of ATL1103, and administered with the same or increased or lower dosing frequency to achieve the desired target IGF-I levels, and optinally GH levels and outcomes in cancer."